{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:34:58Z","timestamp":1790962498631,"version":"4.1.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2023.18570"],"award-info":[{"award-number":["2023.18570"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.drudis.2026.104615","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T23:23:19Z","timestamp":1769296999000},"page":"104615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive value of the hERG assay for anticipating the arrhythmogenic potential of new drugs"],"prefix":"10.1016","volume":"31","author":[{"given":"Carlos A.","family":"Matos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuro","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Augusto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rog\u00e9rio","family":"Algarvio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Figueirinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6201-3662","authenticated-orcid":false,"given":"Jaime","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104615_b0005","unstructured":"The European regulatory system for medicines. A consistent approach to medicines regulation across the European Union. EMA\/716925\/2016. European Medicines Agency (EMA); 2016."},{"key":"10.1016\/j.drudis.2026.104615_b0010","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1038\/s41598-024-53554-7","article-title":"Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980\u20132022","volume":"14","author":"Seoane-Vazquez","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104615_b0015","article-title":"Carbamazepine bilayer tablets combining hydrophilic and hydrophobic cyclodextrins as a quick\/slow biphasic release system","volume":"57","author":"Concei\u00e7\u00e3o","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.drudis.2026.104615_b0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacbts.2016.03.002","article-title":"Drugs, devices, and the FDA: Part 1: an overview of approval processes for drugs","volume":"1","author":"Van Norman","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.drudis.2026.104615_b0025","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104615_b0030","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ph16091283","article-title":"Research in the field of drug design and development","volume":"16","author":"Biala","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2026.104615_b0035","unstructured":"Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH); 2009."},{"key":"10.1016\/j.drudis.2026.104615_b0040","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3389\/fchem.2020.00726","article-title":"Computational approaches in preclinical studies on drug discovery and development","volume":"8","author":"Wu","year":"2020","journal-title":"Front Chem"},{"key":"10.1016\/j.drudis.2026.104615_b0045","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41573-022-00633-x","article-title":"The evolving role of investigative toxicology in the pharmaceutical industry","volume":"22","author":"Pognan","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104615_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2025.105795","article-title":"Points to consider for revising the ICH S7A guideline on safety and secondary pharmacology","volume":"159","author":"Valentin","year":"2025","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0055","article-title":"Rising with cardio-oncology: clinical considerations of cardiotoxicity with select anticancer drug therapies","author":"Chung","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.drudis.2026.104615_b0060","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/cvr\/cvaf095","article-title":"Adverse cardiac events associated with antibody-drug conjugates in cancer patients: retrospective analysis of FAERS database and RCTs","volume":"121","author":"Zhuang","year":"2025","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.drudis.2026.104615_b0065","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00204-018-2152-9","article-title":"Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms","volume":"92","author":"Pridgeon","year":"2018","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.drudis.2026.104615_b0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-3-662-46943-9_7","article-title":"Biophysics and molecular biology of cardiac ion channels for the safety pharmacologist","volume":"229","author":"Pugsley","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0075","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1208\/s12248-015-9773-1","article-title":"Early drug discovery prediction of proarrhythmia potential and its covariates","volume":"17","author":"Polak","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.drudis.2026.104615_b0080","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00204-015-1651-1","article-title":"Cardiotoxicity screening: a review of rapid-throughput in vitro approaches","volume":"90","author":"Li","year":"2016","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.drudis.2026.104615_b0085","article-title":"Torsades de pointes following massive transfusion protocol: case highlighting electrolyte disturbances after blood product administration","volume":"30","author":"Khan","year":"2025","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.drudis.2026.104615_b0090","doi-asserted-by":"crossref","DOI":"10.2196\/65872","article-title":"Detection of clinically significant drug-drug interactions in fatal torsades de pointes: disproportionality analysis of the food and drug administration adverse event reporting system","volume":"27","author":"Ji","year":"2025","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.drudis.2026.104615_b0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s10928-025-09979-2","article-title":"A comprehensive review of 20 years of progress in nonclinical QT evaluation and proarrhythmic assessment","volume":"52","author":"Delpy","year":"2025","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.drudis.2026.104615_b0100","series-title":"Stephens' Detection of New Adverse Drug Reactions","author":"Talbot","year":"2004"},{"key":"10.1016\/j.drudis.2026.104615_b0105","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3389\/fphys.2017.00934","article-title":"In vitro and in silico risk assessment in acquired long QT syndrome: the devil is in the details","volume":"8","author":"Lee","year":"2017","journal-title":"Front Physiol"},{"key":"10.1016\/j.drudis.2026.104615_b0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.vascn.2017.04.002","article-title":"Cardiac voltage-gated ion channels in safety pharmacology: review of the landscape leading to the CiPA initiative","volume":"87","author":"Huang","year":"2017","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0115","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40263-025-01163-x","article-title":"Cardiovascular effects of antiseizure medications for epilepsy","volume":"39","author":"Nei","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drudis.2026.104615_b0120","doi-asserted-by":"crossref","DOI":"10.1080\/20523211.2024.2399716","article-title":"Association of anxiolytic drugs with Torsade de Pointes: a pharmacovigilance study of the Food and Drug Administration adverse event reporting system","volume":"17","author":"Ali","year":"2024","journal-title":"J Pharm Policy Pract"},{"key":"10.1016\/j.drudis.2026.104615_b0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/DHPS.S133286","article-title":"Evaluating cardiac risk: exposure response analysis in early clinical drug development","volume":"10","author":"Grenier","year":"2018","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.drudis.2026.104615_b0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coph.2013.11.004","article-title":"Cardiac safety assays","volume":"15","author":"Heijman","year":"2014","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0135","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1089\/ten.tec.2017.0247","article-title":"Development of in vitro drug-induced cardiotoxicity assay by using three-dimensional cardiac tissues derived from human induced pluripotent stem cells","volume":"24","author":"Takeda","year":"2018","journal-title":"Tissue Eng Part C Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0140","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3390\/ph16111509","article-title":"Derivation of highly predictive 3D-QSAR models for hERG channel blockers based on the quantum artificial neural network algorithm","volume":"16","author":"Kim","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2026.104615_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2016.02.181","article-title":"The prospective IQ-CSRC trial: a prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study","volume":"80","author":"Cavero","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0150","unstructured":"ICH Harmonised Tripartite Guideline S7B. The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. International Conference on Harmonisation (ICH); 2005."},{"key":"10.1016\/j.drudis.2026.104615_b0155","unstructured":"ICH Harmonised Tripartite Guideline E14. The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. International Conference on Harmonisation (ICH); 2005."},{"key":"10.1016\/j.drudis.2026.104615_b0160","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.drudis.2017.04.017","article-title":"Thorough QT (TQT) studies: concordance with torsadogenesis and an evolving cardiac safety testing paradigm","volume":"22","author":"Wi\u015bniowska","year":"2017","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104615_b0165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cpt.896","article-title":"Mechanistic model-informed proarrhythmic risk assessment of drugs: review of the \u201cCiPA\u201d initiative and design of a prospective clinical validation study","volume":"103","author":"Vicente","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104615_b0170","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/0091270006286436","article-title":"Clinical evaluation of QT\/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use E14 guideline","volume":"46","author":"Darpo","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14\/S7B updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104615_b0180","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"121","author":"Drew","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2026.104615_b0185","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1185\/03007995.2013.840568","article-title":"QT interval prolongation and the risk of torsades de pointes: essentials for clinicians","volume":"29","author":"Trinkley","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.drudis.2026.104615_b0190","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ahj.2007.01.040","article-title":"Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes","volume":"153","author":"Gupta","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.drudis.2026.104615_b0195","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.drudis.2026.104615_b0200","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3390\/ph17101373","article-title":"Assessing the risk of QT prolongation in a psychiatric inpatient cohort: a retrospective cross-sectional study","volume":"17","author":"Christensen","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2026.104615_b0205","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bcp.12726","article-title":"Pharmacological treatment of acquired QT prolongation and torsades de pointes","volume":"81","author":"Thomas","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0210","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0735-1097(84)80232-6","article-title":"Long QT: good, bad or indifferent?","volume":"4","author":"Surawicz","year":"1984","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.drudis.2026.104615_b0215","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3390\/ijms20061324","article-title":"QT assessment in early drug development: the long and the short of it","volume":"20","author":"Lester","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104615_b0220","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/jcph.1129","article-title":"Drug-induced proarrhythmia and torsade de pointes: a primer for students and practitioners of medicine and pharmacy","volume":"58","author":"Turner","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0225","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.taap.2009.12.002","article-title":"The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?","volume":"243","author":"Lee","year":"2010","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0230","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.drudis.2026.104615_b0235","first-page":"263","article-title":"Ventricular tachycardia with 2 variable opposing foci","volume":"59","author":"Dessertenne","year":"1966","journal-title":"Arch Mal Coeur Vaiss"},{"key":"10.1016\/j.drudis.2026.104615_b0240","first-page":"473","article-title":"Drug-induced QT prolongation and torsades de pointes","volume":"42","author":"Li","year":"2017","journal-title":"P T"},{"key":"10.1016\/j.drudis.2026.104615_b0245","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pbiomolbio.2016.03.004","article-title":"Disturbances of cardiac wavelength and repolarization precede torsade de pointes and ventricular fibrillation in Langendorff perfused rabbit hearts","volume":"121","author":"Hondeghem","year":"2016","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1016\/j.drudis.2026.104615_b0250","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","article-title":"Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes","volume":"67","author":"Schwartz","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.drudis.2026.104615_b0255","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2217\/pgs-2023-0229","article-title":"Genetic risk factors for drug-induced long QT syndrome: findings from a large real-world case-control study","volume":"25","author":"Lopez-Medina","year":"2024","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.drudis.2026.104615_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1363848","article-title":"Mechanisms of torsades de pointes: an update","volume":"11","author":"Tsuji","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.drudis.2026.104615_b0265","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14740338.2024.2392002","article-title":"An updated safety review of the relationship between atypical antipsychotic drugs, the QTc interval and torsades de pointe as: implications for clinical use","volume":"23","author":"Melo","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.drudis.2026.104615_b0270","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.hrthm.2024.02.007","article-title":"Top stories: drug-induced long QT syndrome","volume":"21","author":"Woosley","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.drudis.2026.104615_b0275","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/ph18020230","article-title":"Sacubitril does not exert proarrhythmic effects in combination with different antiarrhythmic drugs","volume":"18","author":"Ellermann","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2026.104615_b0280","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0092-8674(95)90340-2","article-title":"A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel","volume":"81","author":"Sanguinetti","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104615_b0285","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1126\/science.7604285","article-title":"HERG, a human inward rectifier in the voltage-gated potassium channel family","volume":"269","author":"Trudeau","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104615_b0290","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.vascn.2013.03.005","article-title":"A history of the role of the hERG channel in cardiac risk assessment","volume":"68","author":"Rampe","year":"2013","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0295","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-1-4939-7172-5_10","article-title":"Automated patch-clamp methods for the hERG cardiac potassium channel","volume":"1641","author":"Houtmann","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2026.104615_b0300","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/mol.117.111534","article-title":"The temperature dependence of kinetics associated with drug block of hERG channels is compound-specific and an important factor for proarrhythmic risk prediction","volume":"94","author":"Windley","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0305","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.vascn.2016.05.005","article-title":"A temperature-dependent in silico model of the human ether-\u00e0-go-go-related (hERG) gene channel","volume":"81","author":"Li","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0310","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.vascn.2005.07.003","article-title":"Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends","volume":"53","author":"Hoffmann","year":"2006","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0315","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/phar.2087","article-title":"Validation and clinical utility of the hERG IC50:Cmax ratio to determine the risk of drug-induced torsades de pointes: a meta-analysis","volume":"38","author":"Lehmann","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.drudis.2026.104615_b0320","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.addr.2015.03.003","article-title":"Computational investigations of hERG channel blockers: new insights and current predictive models","volume":"86","author":"Villoutreix","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2026.104615_b0325","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1111\/bph.13207","article-title":"Evaluation of drug-induced QT interval prolongation in animal and human studies: a literature review of concordance","volume":"172","author":"Vargas","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0330","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1586\/14779072.2016.1116940","article-title":"A 2015 focus on preventing drug-induced arrhythmias","volume":"14","author":"Bossu","year":"2016","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.drudis.2026.104615_b0335","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3390\/ph16091204","article-title":"Inhibition of the hERG potassium channel by a methanesulphonate-free E-4031 analogue","volume":"16","author":"Helliwell","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2026.104615_b0340","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/joa3.12741","article-title":"Pharmacological activation of the hERG K+ channel for the management of the long QT syndrome: a review","volume":"38","author":"Harchi","year":"2022","journal-title":"J Arrhythm"},{"key":"10.1016\/j.drudis.2026.104615_b0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1087057115594589","article-title":"A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm","volume":"21","author":"Fermini","year":"2016","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.drudis.2026.104615_b0350","unstructured":"ICH Harmonised Tripartite Guideline S7A. Safety Pharmacology Studies for Human Pharmaceuticals. International Conference on Harmonisation (ICH); 2000."},{"key":"10.1016\/j.drudis.2026.104615_b0355","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14740338.4.3.509","article-title":"ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis","volume":"4","author":"Cavero","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.drudis.2026.104615_b0360","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00002018-200528020-00003","article-title":"Drugs, QT interval prolongation and ICH E14: the need to get it right","volume":"28","author":"Shah","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.drudis.2026.104615_b0365","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2165\/00002018-200528110-00003","article-title":"Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead","volume":"28","author":"Shah","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.drudis.2026.104615_b0370","unstructured":"Guidance for Industry E14. Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs \u2013 Questions and Answers (R3). Food and Drug Administration (FDA), U.S. Department of Health and Human Services; 2017."},{"key":"10.1016\/j.drudis.2026.104615_b0375","unstructured":"ICH guideline E14: The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs (R3) \u2013 questions and answers. European Medicines Agency (EMA), Committee for Human Medicinal Products (CHMP); 2016."},{"key":"10.1016\/j.drudis.2026.104615_b0380","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/jcph.1880","article-title":"The new S7B\/E14 question and answer draft guidance for industry: contents and commentary","volume":"61","author":"Darpo","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0385","unstructured":"Final Concept Paper \u2013 ICH E14\/S7B IWG Recommended Round 2 Q&As. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH); 2024."},{"key":"10.1016\/j.drudis.2026.104615_b0390","unstructured":"ICH E14\/S7B IWG Work Plan. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH); 2025."},{"key":"10.1016\/j.drudis.2026.104615_b0395","unstructured":"ICH E14\/S7B IWG Work Plan. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH); 2024."},{"key":"10.1016\/j.drudis.2026.104615_b0400","first-page":"191294","article-title":"Safety information on QT-interval prolongation: comparison of European Union and United States drug labeling","author":"Warnier","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104615_b0405","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2014.06.019","article-title":"The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports","volume":"68","author":"Schroll","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.drudis.2026.104615_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112290","article-title":"hERG toxicity assessment: useful guidelines for drug design","volume":"195","author":"Garrido","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104615_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2021.107055","article-title":"Core battery safety pharmacology testing \u2013 an assessment of its utility in early drug development","volume":"109","author":"Baldrick","year":"2021","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0420","unstructured":"ICH guideline E14\/S7B: Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential \u2013 questions and answers. EMA\/CHMP\/ICH\/415588\/2020. European Medicines Agency (EMA); 2022."},{"key":"10.1016\/j.drudis.2026.104615_b0425","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","article-title":"The comprehensive in vitro proarrhythmia assay (CiPA) initiative \u2013 update on progress","volume":"81","author":"Colatsky","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0430","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.94.4.817","article-title":"HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine","volume":"94","author":"Roy","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2026.104615_b0435","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0014-5793(96)00355-9","article-title":"Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole","volume":"385","author":"Suessbrich","year":"1996","journal-title":"FEBS Lett"},{"key":"10.1016\/j.drudis.2026.104615_b0440","first-page":"H2534","article-title":"Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride","volume":"273","author":"Mohammad","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.drudis.2026.104615_b0445","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0014-5793(97)01249-0","article-title":"A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG","volume":"417","author":"Rampe","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.drudis.2026.104615_b0450","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.jelectrocard.2018.08.003","article-title":"Update on the ECG component of the CiPA initiative","volume":"51","author":"Vicente","year":"2018","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.drudis.2026.104615_b0455","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1080\/17512433.2016.1245142","article-title":"Early drug development: assessment of proarrhythmic risk and cardiovascular safety","volume":"9","author":"Lester","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0460","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.drudis.2016.02.003","article-title":"Recent developments in using mechanistic cardiac modelling for drug safety evaluation","volume":"21","author":"Davies","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104615_b0465","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.vascn.2016.09.004","article-title":"Comprehensive in vitro cardiac safety assessment using human stem cell technology: overview of CSAHi HEART initiative","volume":"83","author":"Takasuna","year":"2017","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0470","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/2168479018795117","article-title":"Comprehensive In Vitro Proarrhythmia Assay (CiPA) update from a Cardiac Safety Research Consortium\/Health and Environmental Sciences Institute\/FDA meeting","volume":"53","author":"Strauss","year":"2019","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.drudis.2026.104615_b0475","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bph.14101","article-title":"Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium","volume":"175","author":"Park","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0480","first-page":"687","article-title":"HERG K+ channel, the target of anti-arrhythmias drugs","volume":"42","author":"Guan","year":"2007","journal-title":"Yao Xue Xue Bao"},{"key":"10.1016\/j.drudis.2026.104615_b0485","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4155\/fmc.09.51","article-title":"In vitro safety pharmacology profiling: what else beyond hERG?","volume":"1","author":"Hamon","year":"2009","journal-title":"Future Med Chem"},{"key":"10.1016\/j.drudis.2026.104615_b0490","first-page":"23","article-title":"hERG: Protein trafficking and potential for therapy and drug side effects","volume":"13","author":"Staudacher","year":"2010","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.drudis.2026.104615_b0495","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1755-5922.2010.00154.x","article-title":"Drug-induced hERG block and long QT syndrome","volume":"29","author":"Witchel","year":"2011","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.drudis.2026.104615_b0500","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejphar.2014.06.044","article-title":"hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia","volume":"741","author":"Nogawa","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0505","first-page":"101","article-title":"Progress in research on defective protein trafficking and functional restoration in HERG-associated long QT syndrome","volume":"33","author":"Fang","year":"2016","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"key":"10.1016\/j.drudis.2026.104615_b0510","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.2174\/1568026617666170414143430","article-title":"Computational models for understanding of structure, function and pharmacology of the cardiac potassium channel Kv11.1 (hERG)","volume":"17","author":"Wacker","year":"2017","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.drudis.2026.104615_b0515","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.tips.2017.06.004","article-title":"Towards a structural view of drug binding to hERG K+ channels","volume":"38","author":"Vandenberg","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2026.104615_b0520","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21445","article-title":"Development of safe drugs: the hERG challenge","volume":"38","author":"Kalyaanamoorthy","year":"2018","journal-title":"Med Res Rev"},{"key":"10.1016\/j.drudis.2026.104615_b0525","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neulet.2018.05.019","article-title":"Lipid roles in hERG function and interactions with drugs","volume":"700","author":"Kudaibergenova","year":"2019","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.drudis.2026.104615_b0530","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/164_2021_502","article-title":"Pharmacological approaches to studying potassium channels","volume":"267","author":"Mathie","year":"2021","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0535","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1021\/acs.jcim.2c00256","article-title":"HergSPred: accurate classification of hERG blockers\/nonblockers with machine-learning models","volume":"62","author":"Zhang","year":"2022","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2026.104615_b0540","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/toxsci\/kfac013","article-title":"The challenges of predicting drug-induced QTc prolongation in humans","volume":"187","author":"Valentin","year":"2022","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.drudis.2026.104615_b0545","first-page":"103","article-title":"Beyond pharmaceuticals: fit-for-purpose new approach methodologies for environmental cardiotoxicity testing","volume":"40","author":"Daley","year":"2023","journal-title":"ALTEX"},{"key":"10.1016\/j.drudis.2026.104615_b0550","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.tips.2024.06.003","article-title":"Multiple hERG channel blocking pathways: Implications for macromolecules","volume":"45","author":"Z\u00fcnkler","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2026.104615_b0555","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/cpt.1184","article-title":"Assessment of an in silico mechanistic model for proarrhythmia risk prediction under the CiPA initiative","volume":"105","author":"Li","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104615_b0560","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/cpt.3284","article-title":"Should you run a dedicated TQT study? Sponsor and regulatory considerations on substitution pathways to assess QT liability","volume":"116","author":"Lester","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104615_b0565","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.vascn.2018.06.006","article-title":"Cross \u2013 site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes","volume":"93","author":"Bot","year":"2018","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0570","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2018.06.005","article-title":"CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. an overview of the safety pharmacology scientific discussion","volume":"93","author":"Wallis","year":"2018","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0575","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jelectrocard.2016.07.017","article-title":"Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs","volume":"49","author":"Vicente","year":"2016","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.drudis.2026.104615_b0580","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.vascn.2017.02.017","article-title":"Measuring kinetics and potency of hERG block for CiPA","volume":"87","author":"Windley","year":"2017","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0585","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jelectrocard.2017.08.003","article-title":"Electrocardiographic biomarkers to confirm drug's electrophysiological effects used for proarrhythmic risk prediction under CiPA","volume":"50","author":"Vicente","year":"2017","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.drudis.2026.104615_b0590","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/ehjcvp\/pvw045","article-title":"Recent developments in the science of proarrhythmic cardiac safety of new drugs","volume":"3","author":"Turner","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.drudis.2026.104615_b0595","doi-asserted-by":"crossref","DOI":"10.1063\/1.5132618","article-title":"In silico models for evaluating proarrhythmic risk of drugs","volume":"4","author":"Hwang","year":"2020","journal-title":"APL Bioeng"},{"key":"10.1016\/j.drudis.2026.104615_b0600","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd.2015.34","article-title":"Evolution of strategies to improve preclinical cardiac safety testing","volume":"15","author":"Gintant","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104615_b0605","doi-asserted-by":"crossref","first-page":"145","DOI":"10.12793\/tcp.2018.26.4.145","article-title":"Five years of the CiPA project (2013\u20132018): what did we learn?","volume":"26","author":"Yim","year":"2018","journal-title":"Transl Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0610","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/jat.3611","article-title":"Moving beyond the comprehensive in vitro proarrhythmia assay: use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity","volume":"38","author":"Yang","year":"2018","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.drudis.2026.104615_b0615","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tcm.2017.11.002","article-title":"Pro-arrhythmic effects of low plasma [K+] in human ventricle: an illustrated review","volume":"28","author":"Trenor","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.drudis.2026.104615_b0620","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/psp4.12423","article-title":"Quantitative systems pharmacology models for a new international cardiac safety regulatory paradigm: an overview of the comprehensive in vitro proarrhythmia assay in silico modeling approach","volume":"8","author":"Li","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0625","doi-asserted-by":"crossref","first-page":"12","DOI":"10.12793\/tcp.2019.27.1.12","article-title":"Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative","volume":"27","author":"Park","year":"2019","journal-title":"Transl Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0630","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.vascn.2016.05.012","article-title":"Comprehensive in vitro Proarrhythmia Assay (CiPA): pending issues for successful validation and implementation","volume":"81","author":"Cavero","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0635","unstructured":"ICH E14 Guideline: The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Questions & Answers (R3). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH); 2015."},{"key":"10.1016\/j.drudis.2026.104615_b0640","unstructured":"E14\/S7B Discussion Group (DG) Membership List. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH); 2018."},{"key":"10.1016\/j.drudis.2026.104615_b0645","unstructured":"ICH E14\/S7B DG Work Plan. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH); 2018."},{"key":"10.1016\/j.drudis.2026.104615_b0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106582","article-title":"The West coast regional safety pharmacology society meeting update: filling translational gaps in safety assessment","volume":"98","author":"Abi-Gerges","year":"2019","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0655","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/cpdd.1003","article-title":"Update on ICH E14\/S7B cardiac safety regulations: the expanded role of preclinical assays and the \u201cdouble-negative\u201d scenario","volume":"10","author":"Lester","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.drudis.2026.104615_b0660","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: a pharma industry perspective","volume":"109","author":"Vargas","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104615_b0665","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jcph.2095","article-title":"ECG evaluation as part of the clinical pharmacology strategy in the development of new drugs: a review of current practices and opportunities based on five case studies","volume":"62","author":"Darpo","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0670","volume":"392","author":"Sugiyama","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2026.104615_b0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2023.107270","article-title":"Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14\/S7B Q&As","volume":"123","author":"Rossman","year":"2023","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0680","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/jcph.2309","article-title":"The new S7B\/E14 Q&A document provides additional opportunities to replace the thorough QT study","volume":"63","author":"Darpo","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2023.107300","article-title":"Safety pharmacology 2023 and implementation of the ICH E14\/S7B Q&A guidance document","volume":"123","author":"Pugsley","year":"2023","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2026.104615_b0690","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/cpt.3047","article-title":"ICH S7B in vitro assays do not address mechanisms of QTC prolongation for peptides and proteins \u2013 data in support of not needing dedicated QTC studies","volume":"114","author":"Wu","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104615_b0695","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10928-025-09988-1","article-title":"Lessons learned from QT prolongation risk assessment for antibody-drug conjugates in oncology","volume":"52","author":"Shah","year":"2025","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.drudis.2026.104615_b0700","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.stem.2017.06.005","article-title":"The evolving roles of human iPSC-derived cardiomyocytes in drug safety and discovery","volume":"21","author":"Gintant","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drudis.2026.104615_b0705","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1021\/acs.jcim.0c00884","article-title":"Critical assessment of artificial intelligence methods for prediction of hERG channel inhibition in the \u201cbig Data\u201d era","volume":"60","author":"Siramshetty","year":"2020","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2026.104615_b0710","doi-asserted-by":"crossref","first-page":"13766","DOI":"10.1080\/07391102.2023.2193641","article-title":"Machine-learning technique, QSAR and molecular dynamics for hERG-drug interactions","volume":"41","author":"Das","year":"2023","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.drudis.2026.104615_b0715","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/17425255.2024.2377593","article-title":"Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study","volume":"20","author":"Liu","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.drudis.2026.104615_b0720","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.toxlet.2020.07.003","article-title":"Prediction of hERG potassium channel blockage using ensemble learning methods and molecular fingerprints","volume":"332","author":"Liu","year":"2020","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.drudis.2026.104615_b0725","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.3390\/molecules25112615","article-title":"The study on the hERG blocker prediction using chemical fingerprint analysis","volume":"25","author":"Choi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104615_b0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2021.153018","article-title":"TSSF-hERG: a machine-learning-based hERG potassium channel-specific scoring function for chemical cardiotoxicity prediction","volume":"464","author":"Meng","year":"2021","journal-title":"Toxicology"},{"key":"10.1016\/j.drudis.2026.104615_b0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.crtox.2023.100121","article-title":"hERG-toxicity prediction using traditional machine learning and advanced deep learning techniques","volume":"5","author":"Ylip\u00e4\u00e4","year":"2023","journal-title":"Curr Res Toxicol"},{"key":"10.1016\/j.drudis.2026.104615_b0740","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13321-025-00976-8","article-title":"CardioGenAI: a machine learning-based framework for re-engineering drugs for reduced hERG liability","volume":"17","author":"Kyro","year":"2025","journal-title":"J Cheminform"},{"key":"10.1016\/j.drudis.2026.104615_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105390","article-title":"Combining multi-dimensional molecular fingerprints to predict the hERG cardiotoxicity of compounds","volume":"144","author":"Ding","year":"2022","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.drudis.2026.104615_b0750","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1021\/acs.chemrestox.3c00400","article-title":"Enhancing hERG risk assessment with Interpretable classificatory and regression models","volume":"37","author":"Sanches","year":"2024","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.drudis.2026.104615_b0755","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1021\/acs.chemrestox.5c00065","article-title":"Enlarged data sets and innovative applicability domain characterization empower ML models to reliably bridge hERG binding data gaps in diverse chemicals","volume":"38","author":"Zhang","year":"2025","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.drudis.2026.104615_b0760","doi-asserted-by":"crossref","first-page":"15585","DOI":"10.1038\/s41598-025-99766-3","article-title":"hERG toxicity prediction in early drug discovery using extreme gradient boosting and isometric stratified ensemble mapping","volume":"15","author":"Falc\u00f3n-Cano","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104615_b0765","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13321-025-01063-8","article-title":"HERGAI: an artificial intelligence tool for structure-based prediction of hERG inhibitors","volume":"17","author":"Tran-Nguyen","year":"2025","journal-title":"J Cheminform"},{"key":"10.1016\/j.drudis.2026.104615_b0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.109416","article-title":"hERGBoost: a gradient boosting model for quantitative IC50 prediction of hERG channel blockers","volume":"184","author":"Yu","year":"2025","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.drudis.2026.104615_b0775","first-page":"1","article-title":"hERG-LTN: a new paradigm for hERG cardiotoxicity prediction using neuro-symbolic and generative AI","volume":"2025","author":"Hossain","year":"2025"},{"key":"10.1016\/j.drudis.2026.104615_b0780","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.951083","article-title":"Ligand-based prediction of hERG-mediated cardiotoxicity based on the integration of different machine learning techniques","volume":"13","author":"Delre","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104615_b0785","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1109\/TCBBIO.2025.3614696","article-title":"MTF-hERG: a multi-type features fusion-based framework for predicting hERG cardiotoxicity of compounds","volume":"22","author":"Liu","year":"2025","journal-title":"IEEE Trans Comput Biol Bioinform"},{"key":"10.1016\/j.drudis.2026.104615_b0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.133825","article-title":"MultiCBlo: Enhancing predictions of compound-induced inhibition of cardiac ion channels with advanced multimodal learning","volume":"276","author":"Wang","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2026.104615_b0795","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1021\/acs.jcim.1c00856","article-title":"Toward reducing hERG affinities for DAT inhibitors with a combined machine learning and molecular modeling approach","volume":"61","author":"Lee","year":"2021","journal-title":"J Chem Inf Model"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:04:46Z","timestamp":1778601886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":159,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1359644626000206"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104615","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive value of the hERG assay for anticipating the arrhythmogenic potential of new drugs","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104615"}}